Finder Award
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Clovis Oncology is a biotechnology & medical research business based in the US. Clovis Oncology shares (CLVS) are listed on the NASDAQ and all prices are listed in US Dollars. Clovis Oncology employs 413 staff and has a trailing 12-month revenue of around $133 million.
How to buy Clovis Oncology stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – CLVS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Finder Award
Finder Award
eToro
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
tastytrade
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Clovis Oncology stock price (NASDAQ: CLVS)
Use our graph to track the performance of CLVS stocks over time.Clovis Oncology shares at a glance
Information last updated 2023-02-26.
| Latest market close | $0.09 |
|---|---|
| 52-week range | $0.04 - $3.25 |
| 50-day moving average | $0.41 |
| 200-day moving average | $1.22 |
| Wall St. target price | $2.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.08 |
Buy Clovis Oncology stocks from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 6 of 6
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Clovis Oncology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Clovis Oncology price performance over time
Historical closes compared with the close of $0.093 from 2023-02-22
| 1 week (2023-03-17) | N/A |
|---|---|
| 1 month (2023-02-24) | N/A |
| 3 months (2022-12-28) | 57.63% |
| 6 months (2022-09-28) | -92.12% |
| 1 year (2022-03-24) | N/A |
|---|---|
| 2 years (2021-03-26) | -98.56% |
| 3 years (2020-03-27) | 7.13 |
| 5 years (2018-03-27) | 53.67 |
Is Clovis Oncology stock undervalued or overvalued?
Valuing Clovis Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clovis Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Clovis Oncology's PEG ratio
Clovis Oncology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.13. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Clovis Oncology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Clovis Oncology financials
| Revenue TTM | $133 million |
|---|---|
| Gross profit TTM | $115.3 million |
| Return on assets TTM | -30.18% |
| Return on equity TTM | 0% |
| Profit margin | -189.38% |
| Book value | $-2.89 |
| Market capitalisation | $11.8 million |
TTM: trailing 12 months
Clovis Oncology share dividends
We're not expecting Clovis Oncology to pay a dividend over the next 12 months.
Clovis Oncology share price volatility
Over the last 12 months, Clovis Oncology's shares have ranged in value from as little as $0.0422 up to $3.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Clovis Oncology's is 0.2205. This would suggest that Clovis Oncology's shares are less volatile than average (for this exchange).
Clovis Oncology overview
Clovis Oncology, Inc. , a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U. S. , the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein.
Frequently asked questions
What percentage of Clovis Oncology is owned by insiders or institutions?Currently 1.438% of Clovis Oncology shares are held by insiders and 25.898% by institutions. How many people work for Clovis Oncology?
Latest data suggests 413 work at Clovis Oncology. When does the fiscal year end for Clovis Oncology?
Clovis Oncology's fiscal year ends in December. Where is Clovis Oncology based?
Clovis Oncology's address is: 5500 Flatiron Parkway, Boulder, CO, United States, 80301 What is Clovis Oncology's ISIN number?
Clovis Oncology's international securities identification number is: US1894641000 What is Clovis Oncology's CUSIP number?
Clovis Oncology's Committee on Uniform Securities Identification Procedures number is: 189464100
More guides on Finder
-
What happens if a brokerage firm fails?
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
-
How to Buy Gold Stocks
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
-
Silicon Valley Bank collapse: Which ETFs and stocks are impacted?
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
-
How to Buy Treasury Bills
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
-
SVB collapses: What does it mean for your portfolio?
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
-
How to buy Vanguard VTI Total Stock Market ETF units
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
Ask an Expert